Evolent Prior Authorization Medicaid Updates 2026
Date: 01/13/26
Evolent (Formerly New Century Health) - Prior Authorization Update
Medical Oncology, Radiation Oncology, Pediatric and Dose Optimization
Effective April 1, 2026
Starting April 1, 2026, additional procedure codes will require prior authorizations through Evolent. This update also includes codes no longer covered by AHCCCS.
Applies to: Arizona Complete Health-Complete Care Plan (Medicaid) only.
Key Medicaid Reminders
- Drugs from manufacturers not participating in the CMS Medicaid Drug Rebate Program (MDRP) are not are not covered
- The transition to preferred biosimilars (approved at the May AHCCCS Pharmacy and Therapeutics (P&T) Committee meeting) became effective August 1, 2025
- All new drugs and biosimilars are non-preferred until reviewed by AHCCCS P&T committee
- Pharmacists may substitute only if the biosimilar has FDA interchangeable status
- If no interchangeable designation exists, prescriber approval is required before dispensing
- Providers must transition patients promptly to the AHCCCS-preferred biosimilars to avoid non-payment
- Submit prior authorization requests via the Evolent Provider Portal:
Utilization Management Categories
Utilization Management Category | Description |
PA Required | Prior Authorizations required for all providers. Requests should be submitted to Evolent |
Not a covered benefit | Drug or HCPCS Code is not covered by AHCCCS |
No PA is required | No Prior Authorization is required for any provider |
PA Required for Non-PAR Providers Only | Prior Authorization required for providers who are not contracted within the health plan network. Requests should be submitted to Evolent |
Questions?
Contact your Provider Engagement Account Manager. Need contact information? Email:
📧 AzCHProviderEngagement@azcompletehealth.com
CODE | MEDICATION | DOSE | Utilization Management |
| ANTI-EMETICS |
|
|
J1456 | INJECT FOSAPREPITANT NOT THERAP EQUIV J1453 | 1 MG | PA Required |
J1626 | INJ GRANISETRON HYDROCHLORIDE | 100 MCG | PA Required for Non-PAR Providers Only |
J2469 | INJECTION PALONOSETRON HCL | 25 MCG | PA Required for Non-PAR Providers Only |
Q0162 | ONDAN 1 MG ORL NOT EXCEED 48 HR DOS | 1 MG | PA Required for Non-PAR Providers Only |
Q0166 | GRANISETRON HCL ORAL CHEMO ANTI-EMETIC | 1 MG | PA Required for Non-PAR Providers Only |
| BONE METS |
|
|
J0897 | DENOSUMAB INJECTION (Prolia/Xgeva) | 1 MG | PA Required |
J2430 | INJ PAMIDRONATE DISODIUM | 30 MG | PA Required |
J3590 | DENOSUMAB-QBDE (Enoby/Xtrenbo) | 1mg | Not a Covered Benefit |
J3590 | DENOSUMAB-KYQQ (Aukelso/Bosaya) | 1mg | Not a Covered Benefit |
J3590 | DENOSUMAB-NXXP (Bildyos/Bilprevda) | 1mg | Not a Covered Benefit |
Q5158 | DENOSUMAB-BNHT (Bomyntra/Conexxence) | 1mg | Not a Covered Benefit |
Q5157 | DENOSUMAB-BMWO (Stobocio/Osenvelt) | 1mg | Not a Covered Benefit |
Q5159 | DENOSUMAB-DSSB (Ospomyv/Xbyrk) | 1mg | Not a Covered Benefit |
Q5136 | DENOSUMAB-BBDZ (Jubbonti/Wyost) | 1mg | Not a Covered Benefit |
J3489 | ZOLEDRONIC ACID | 1MG | PA Required |
| CANCER TREATMENT |
|
|
C9155 | INJECTION EPCORITAMAB-BYSP | 0.16 MG | Not a Covered Benefit |
C9163 | INJECTION TALQUETAMAB-TGVS | 0.25 MG | Not a Covered Benefit |
C9165 | INJECTION ELRANATAMAB-BCMM | 1 MG | Not a Covered Benefit |
J0202 | INJECTION ALEMTUZUMAB | 1 MG | PA Required |
J0594 | INJECTION BUSULFAN | 1 MG | PA Required |
J0640 | INJ LEUCOVORIN CALCIUM PER | 50 MG | PA Required |
J0641 | INJECTION LEVOLEUCOVORIN NOS | 0.5 MG | PA Required |
J0642 | Injection, levoleucovorin (Khapzory) | 0.5 mg | PA Required |
J0791 | INJECTION CRIZANLIZUMAB-TMCA | 5 MG | PA Required |
J0893 | INJECTION DECITABINE NOT THR EQUIV TO J0894 | 1 MG | PA Required |
J0894 | INJECTION DECITABINE | 1 MG | PA Required |
J1050 | MEDROXYPROGESTERONE ACETATE | 1 MG | PA Required for Non-PAR Providers Only |
J1246 | INJECTION DINUTUXIMAB | 0.1 MG | Not a Covered Benefit |
J1950 | INJ LEUPROLIDE ACETATE PER | 3.75 MG | PA Required |
J1952 | LEUPROLIDE INJECTABLE CAMCEVI, | 1 MG | PA Required |
J1954 | INJECTION LA FOR DEPOT SUSPENSION | 7.5 MG | PA Required |
J2860 | INJECTION SILTUXIMAB | 10 MG | PA Required |
J3240 | INJ THYROTROPIN PROV 1.1 VIAL | .9 MG | PA Required |
|
|
|
|
CODE | MEDICATION | DOSE | Utilization Management |
J3315 | INJ TRIPTORELIN PAMOATE | 3.75 MG | PA Required |
J3316 | INJECTION TRIPTORELIN EXTENDED-RELEASE | 3.75 MG | PA Required |
J7308 | AMINOLEVULINIC ACID HCI FOR TICL ADMIN, 20%/1UNIT DOSAGE FORM | 354MG | PA Required for Non-PAR Providers Only |
J7502 | CYCLOSPORINE, ORAL, SOL | 100 MG | PA Required |
J7504 | LYMPHOCYTE IMMUNE/ANTITHYMOCYTE GLOBULIN | 5ML EA | PA Required |
J7512 | PDN IMMED RLSE/DELAY RLSE ORAL | 1 MG | PA Required for Non-PAR Providers Only |
J7520 | SIROLIMUS ORAL | 1 MG | PA Required for Non-PAR Providers Only |
J7527 | ORAL EVEROLIMUS | 0.25 MG | PA Required |
J8510 | BUSULFAN, ORAL | 2 MG | PA Required |
J8522 | CAPECITABINE, ORAL | 50 MG | PA Required |
J8530 | CYCLOPHOSPHAMIDE ORAL | 25 MG | PA Required |
J8560 | ETOPOSIDE ORAL | 50 MG | PA Required |
J8600 | MELPHALAN ORAL | 2 MG | PA Required |
J8610 | METHOTREXATE ORAL | 2.5 MG | PA Required |
J8612 | METHOTREXATE ORAL (xatmep) | 2.5 MG | PA Required for Non-PAR Providers Only |
| CANCER TREATMENT |
|
|
J8700 | TEMOZOLOMIDE ORAL | 5 MG | PA Required |
J8705 | Topotecan, oral | 0.25 mg | PA Required |
J8999 | PRESCRIPTION DRUG-ORAL-CHEMOTHERAPEUTIC-NOS | N/A | Not a Covered Benefit |
J9000 | INJECTION DOXORUBICIN HCL | 10 MG | PA Required |
J9001 | INJECTION DOXORUBICIN HCL, all lipid formulations | 10 MG | Not a Covered Benefit |
Q2050 | INJECTION DOXORUBICIN HCL, LIPOSOMAL, not otherwise specified | 10 MG | PA Required |
J9002 | INJECTION DOXORUBICIN HCL, LIPOSOMAL, doxil | 10 MG | Not a Covered Benefit |
Q2049 | INJECTION DOXORUBICIN HCL, LIPOSOMAL, imported Lipodox | 10 MG | PA Required |
J9015 | ALDESLEUKIN INJECTION | PER VIAL | Not a Covered Benefit |
J9017 | INJECTION ARSENIC TRIOXIDE | 1 MG | PA Required |
J9019 | ERWINAZE INJECTION | 1000 U | PA Required |
J9021 | INJECT ASPARAGINASE RECOMBINANT (RYLAZE) | 0.1 MG | PA Required |
J9022 | INJECTION ATEZOLIZUMAB | 10 MG | PA Required |
J9023 | INJECTION AVELUMAB | 10 MG | PA Required |
J9025 | INJECTION AZACITIDINE | 1 MG | PA Required |
J9027 | INJECTION CLOFARABINE | 1 MG | PA Required |
J9029 | IVES INSTAL NADOFARAGN FIRADENOVC-VNCG PER THR D | PER VIAL | PA Required |
J9030 | BCG LIVE INTRAVESICAL INSTILLATION | 1 MG | PA Required |
CODE | MEDICATION | DOSE | Utilization Management | |
| J9032 | INJECTION BELINOSTAT | 10 MG | PA Required |
| J9033 | INJECTION BENDAMUSTINE HCL (Used for Treanda and its generic equivalents | 1 MG | PA Required |
| J9034 | INJ. INJECTION BENDAMUSTINE HCL (Bendeka) | 1 MG | PA Required |
| J9035 | INJECTION BEVACIZUMAB | 10 MG | PA Required for Non-PAR Providers Only |
| J9036 | INJECTION BENDAMUSTINE HYDROCHLORIDE (Belrapzo) | 1 MG | Not a Covered Benefit |
| J9037 | Injection, belantamab mafodotin-blmf | 0.5 MG | Not a Covered Benefit |
| J9039 | INJECTION BLINATUMOMAB | 1 MCG | PA Required |
| J9040 | BLEOMYCIN SULFATE INJECTION | 15 units | PA Required |
| J9041 | INJECTION BORTEZOMIB | 0.1 MG | PA Required |
| J9042 | BRENTUXIMAB VEDOTIN INJ | 1 MG | PA Required |
| J9043 | CABAZITAXEL INJECTION (Jevtana) | 1 MG | PA Required |
| J9045 | INJECTION CARBOPLATIN | 50 MG | PA Required |
| J9046 | INJ BORTEZOMIB NOT THER EQUIV TO J9041 | 0.1 MG | PA Required |
| J9047 | INJECTION, CARFILZOMIB | 1 MG | PA Required |
| J9048 | INJ BTZ FRESENIUS KABI NOT TX EQV TO J9041 | 0.1MG | PA Required |
| J9049 | INJ BORTEZOMB HOSPIRA NOT TX EQV TO J9041 | 0.1 MG | PA Required |
| J9050 | INJECTION CARMUSTINE | 100 MG | PA Required |
| J9051 | Injection, bortezomib (MAIA), not therapeutically equivalent to J9041 | 0.1 mg | PA Required |
| J9052 | Injection, carmustine (Accord), not therapeutically equivalent to J9050 | 100 mg | PA Required |
| J9055 | INJECTION CETUXIMAB | 10 MG | PA Required |
| J9056 | INJECTION BENDAMUSTINE HCL (Vivimusta) | 1 MG | PA Required |
| J9057 | Injection, copanlisib | 1 mg | PA Required |
| J9058 | INJECTION BENDAMUSTINE HCL (Apotex) | 1 MG | Not a Covered Benefit |
| J9059 | INJECTION BENDAMUSTINE HCL (Baxter) | 1 MG | Not a Covered Benefit |
| J9060 | CISPLATIN INJECTION | 10 MG | PA Required |
| J9061 | INJECTION, AMIVANTAMAB-VMJW | 2 MG | PA Required |
| J9063 | INJECTION MIRVETUXIMAB SORAVTANSINE-GYNX | 1 MG | PA Required |
| J9064 | Injection, cabazitaxel (Sandoz), not therapeutically equivalent to J9043 | 1 mg | Not a Covered Benefit |
| J9065 | INJ CLADRIBINE PER | 1 MG | PA Required |
| J9070 | CYCLOPHOSPHAMIDE | 100MG | Not a Covered Benefit |
| J9071 | INJECTION CYCLOPHOSPHAMIDE (Auromedics) | 5 MG | PA Required for Non-PAR Providers Only |
| J9072 | INJECTION CYCLOPHOSPHAMIDE (Frindovyx) | 5 MG | PA Required |
| J9073 | INJECTION CYCLOPHOSPHAMIDE (Dr Reddy's) | 5 MG | PA Required |
| J9074 | INJECTION CYCLOPHOSPHAMIDE (Sandoz) | 5 MG | PA Required |
| J9075 | INJECTION CYCLOPHOSPHAMIDE (not otherwise specified) | 5 MG | PA Required |
| J9076 | INJECTION CYCLOPHOSPHAMIDE (Baxter) | 5 MG | Not a Covered Benefit |
CODE | MEDICATION | DOSE | Utilization Management | |
| J9098 | CYTARABINE LIPOSOME INJ | 10 MG | Not a Covered Benefit |
| J9100 | INJECTION CYTARABINE | 100 MG | PA Required |
| J9118 | INJECTION CALASPARGASE PEGOL-MKNL | 10 UNITS | PA Required |
| J9119 | INJECTION CEMIPLIMAB-RWLC | 1 MG | PA Required |
| J9120 | INJECTION DACTINOMYCIN | 0.5 MG | PA Required |
| J9130 | DACARBAZINE | 100 MG | PA Required |
| J9144 | INJECTION DARATUMUMAB 10 MG AND HYALURONIDASE FIHJ | 10 MG | PA Required |
| J9145 | INJECTION DARATUMUMAB | 10 MG | PA Required |
| J9150 | INJECTION DAUNORUBICIN | 10 MG | PA Required |
| J9153 | INJECTION LIPOSOMAL 1 MG DNR AND 2.27 MG CA | 1 MG/2.27 MG | PA Required |
| J9155 | DEGARELIX INJECTION | 1 MG | PA Required |
| J9171 | DOCETAXEL INJECTION | 1 MG | PA Required |
| J9172 | INJECTION DOCETAXEL (Docivyx) | 1 MG | Not a Covered Benefit |
| J9173 | INJECTION DURVALUMAB | 10 MG | PA Required |
| J9174 | INJECTION DOCETAXEL (Beizray) | 10 MG | PA Required |
| J9176 | INJECTION ELOTUZUMAB | 1MG | PA Required |
| J9177 | INJECTION ENFORTUMAB VEDOTIN-EJFV | 0.25 MG | PA Required |
| J9178 | INJECTION, EPIRUBICIN HCI | 2 MG | PA Required |
| J9179 | ERIBULIN MESYLATE INJECTION | 0.1 MG | PA Required |
| J9181 | INJECTION ETOPOSIDE | 10 MG | PA Required |
| J9185 | FLUDARABINE PHOSPHATE INJ | 50 MG | PA Required |
| J9190 | INJECTION FLUOROURACIL | 500 MG | PA Required |
| J9196 | INJ GEMCITABINE HCI NOT THR EQUIV J9201 | 200 MG | PA Required |
| J9198 | INJ GEMCITABINE HYDROCHLORIDE INFUGEM | 100 MG | PA Required |
| J9200 | INJECTION FLOXURIDINE | 500 MG | PA Required |
| J9201 | INJECTION GEMCITABINE HCL NOS | 200 MG | PA Required |
| J9202 | GOSERELIN ACETATE IMPLANT PER | 3.6 MG | Not a Covered Benefit |
| J9203 | INJ GEMTUZUMAB OZOGAMICIN | 0.1 MG | PA Required |
| J9204 | INJECTION MOGAMULIZUMAB-KPKC | 1 MG | PA Required |
| J9205 | INJ IRINOTECAN LIPOSOME | 1 MG | PA Required |
| J9206 | INJECTION IRINOTECAN | 20 MG | PA Required |
| J9207 | IXABEPILONE INJECTION | 1 MG | PA Required |
| J9208 | IFOSFAMIDE INJECTION | 1 GM | PA Required |
| J9209 | INJECTION MESNA | 200 MG | PA Required |
| J9210 | INJECTION EMAPALUMAB-LZSG | 1 MG | PA Required |
| J9211 | INJECTION IDARUBICIN HCL | 5 MG | PA Required |
| J9214 | INTERFERON ALFA-2B INJ | 1 million Units | PA Required |
| J9217 | LEUPROLIDE ACETATE FOR DEPOT SUSPENSION | 7.5 MG | PA Required |
CODE | MEDICATION | DOSE | Utilization Management | |
| J9218 | LEUPROLIDE ACETATE PER | 1 MG | PA Required |
| J9223 | INJECTION LURBINECTEDIN | 0.1 MG | PA Required |
| J9227 | INJECTION ISATUXIMAB-IRFC | 10 MG | PA Required |
| J9228 | IPILIMUMAB INJECTION | 1 MG | PA Required |
| J9229 | INJECTION INOTUZUMAB OZOGAMICIN | 0.1 MG | PA Required |
| J9230 | MECHLORETHAMINE HCL INJ | 10 MG | Not a Covered Benefit |
| J9245 | INJECTION MELPHALAN HCI NOS | 50 MG | PA Required |
| J9246 | INJECTION MELPHALAN EVOMELA | 1 MG | PA Required |
| J9247 | Injection, melphalan flufenamide | 1 mg | Not a Covered Benefit |
| J9255 | INJ METHOTREXATE NOT THR EQV TO J9260 | 50 MG | Not a Covered Benefit |
| J9260 | INJECTION METHOTREXATE SODIUM | 50 MG | PA Required |
| J9261 | INJECTION NELARABINE | 50 MG | PA Required |
| J9262 | Injection, omacetaxine mepesuccinate | 0.01 mg | PA Required |
| J9263 | INJECTION, OXALIPLATIN | 0.5 MG | PA Required |
| J9264 | INJECTION PACLITAXEL PROTEIN-BOUND PARTICLES | 1 MG | PA Required |
| J9266 | PEGASPARGASE INJECTION | PER VIAL | PA Required |
| J9267 | PACLITAXEL INJECTION | 1 MG | PA Required |
| J9268 | INJECTION PENTOSTATIN | 10 MG | PA Required |
| J9269 | INJECTION TAGRAXOFUSP-ERZS | 10 MCG | PA Required |
| J9271 | INJECTION PEMBROLIZUMAB | 1 MG | PA Required |
| J9272 | INJECTION, DOSTARLIMAB-GXLY | 10 MG | PA Required |
| J9273 | INJECTION, TISOTUMAB VEDOTIN-TFTV | 1 MG | PA Required |
| J9274 | INJECTION TEBENTAFUSP-TEBN | 1 MCG | PA Required |
| J9280 | MITOMYCIN INJECTION | 5 MG | PA Required |
| J9281 | MITOMYCIN PYELOCALYCEAL INSTILLATION | 1 MG | PA Required |
| J9285 | Injection, olaratumab | 10 mg | Not a Covered Benefit |
| J9286 | INJECTION GLOFITAMAB-GXBM | 2.5 MG | PA Required |
| J9293 | INJ MITOXANTRONE HYDROCHLORIDE PER | 5 MG | PA Required |
| J9294 | INJECTN PEMETREXED HOSPIRA NOT EQUIV J9305 | 10 MG | PA Required |
| J9295 | INJECTION NECITUMUMAB | 1 MG | PA Required |
| J9296 | INJECTN PEMETREXED ACCORD NOT EQUIV J9305 | 10 MG | PA Required |
| J9297 | INJ PEMETREXED SANDOZ NOT THR EQUIV J9305 | 10 MG | PA Required |
| J9298 | INJECTION NIVOLUMAB AND RELATLIMAB-RMBW | 3 MG/1 MG | PA Required |
| J9299 | INJECTION NIVOLUMAB | 1 MG | PA Required |
| J9301 | OBINUTUZUMAB INJ | 10 MG | PA Required |
| J9302 | OFATUMUMAB INJECTION | 10 MG | PA Required |
| J9303 | PANITUMUMAB INJECTION | 10 MG | PA Required |
| J9304 | INJECTION PEMETREXED PEMFEXY | 10 MG | Not a Covered Benefit |
| J9305 | INJECTION PEMETREXED NOS | 10 MG | PA Required |
CODE | MEDICATION | DOSE | Utilization Management | |
| J9306 | INJECTION, PERTUZUMAB | 1 MG | PA Required |
| J9307 | PRALATREXATE INJECTION | 1 MG | PA Required |
| J9308 | INJECTION RAMUCIRUMAB | 5 MG | PA Required |
| J9309 | INJECTION POLATUZUMAB VEDOTIN-PIIQ | 1 MG | PA Required |
| J9311 | INJECTION RITUXIMAB 10 MG AND HYALURONIDASE | 10 MG | PA Required |
| J9312 | INJECTION RITUXIMAB | 10 MG | PA Required |
| J9313 | Injection, moxetumomab pasudotox-tdfk | 0.01 mg | PA Required |
| J9314 | INJECTION PEMETREXED TEVA NOT EQUIV J9305 | 10 MG | PA Required |
| J9316 | INJ PERTUZUMAB TRASTUZUMAB AND HYAL ZZXF PER | 10 MG | PA Required |
| J9317 | INJECTION SACITUZUMAB GOVITECAN HZIY | 2.5 MG | PA Required |
| J9318 | INJECTION ROMIDEPSIN NONLYOPHILIZED | 0.1 MG | PA Required |
| J9319 | INJECTION ROMIDEPSIN LYOPHILIZED | 0.1 MG | PA Required |
| J9320 | Injection, streptozocin | 1 g | PA Required |
| J9321 | INJECTION EPCORITAMAB-BYSP | 0.16 MG | PA Required |
| J9322 | INJ PEMETREXED BLUEPOINT NOT EQUIV J9305 | 10 MG | PA Required |
| J9323 | INJ PEMETREXED DITROMETHAMINE | 10 MG | PA Required |
| J9324 | INJECTION PEMETREXED | 10 MG | PA Required |
| J9325 | INJ TALIMOGENE LAHERPAREPVEC | 1 million Units | PA Required |
| J9328 | TEMOZOLOMIDE INJECTION | 1 MG | PA Required |
| J9330 | TEMSIROLIMUS INJECTION | 1 MG | PA Required |
| J9331 | INJECTION SIROLIMUS PROTEIN-BOUND PARTICLES | 1 MG | PA Required |
| J9340 | INJECTION THIOTEPA | 15 MG | PA Required |
| J9345 | Injection, retifanlimab-dlwr | 1 mg | PA Required |
| J9347 | INJECTION TREMELIMUMAB-ACTL | 1 MG | PA Required |
| J9348 | INJECTION NAXITAMAB-GQGK | 1 MG | PA Required |
| J9349 | INJECTION TAFASITAMAB-CXIX | 2 MG | PA Required |
| J9350 | INJECTION MOSUNETUZUMAB-AXGB | 1 MG | PA Required |
| J9351 | TOPOTECAN INJECTION | 1 MG | PA Required |
| J9352 | INJECTION TRABECTEDIN | 0.1MG | PA Required |
| J9353 | INJECTION MARGETUXIMAB-CMKB | 5 MG | Not a Covered Benefit |
| J9354 | INJ, ADO-TRASTUZUMAB EMT | 1 MG | PA Required |
| J9355 | INJECTION TRASTUZUMAB EXCLUDES BIOSIMILAR | 10 MG | PA Required |
| J9356 | INJECTION TRASTUZUMAB 10 MG AND HYALURONIDASE-OYSK | 10 MG | PA Required |
| J9357 | Injection, valrubicin, intravesical | 200 mg | PA Required |
| J9358 | INJECTION FAM-TRASTUZUMAB DERUXTECAN-NXKI | 1 MG | PA Required |
| J9359 | INJECTION, LONCASTUXIMAB TESIRINE-LPYL | 0.075 MG | PA Required |
| J9360 | INJECTION VINBLASTINE SULFATE | 1 MG | PA Required |
CODE | MEDICATION | DOSE | Utilization Management | |
| J9370 | VINCRISTINE SULFATE | 1 MG | PA Required |
| J9380 | INJECTOIN TECLISTAMAB-CQYV | 0.5 MG | PA Required |
| J9390 | VINORELBINE TARTRATE INJ | 10 MG | PA Required |
| J9393 | INJECT FULVESTRANT NOT THR EQUIV TO J9395 | 25 MG | PA Required |
| J9394 | INJ FUL FRESENIUS KABI NOT TX EQV TO J9395 | 25 MG | PA Required |
| J9395 | INJECTION, FULVESTRANT | 25 MG | PA Required |
| J9400 | INJ, ZIV-AFLIBERCEPT | 1 MG | PA Required |
| J9600 | PORFIMER SODIUM INJECTION | 75 MG | PA Required |
| J9999 | NOT OTHERWISE CLASSIFIED ANTINEOPLASTIC DRUGS | N/A | PA Required |
| Q2017 | Injection, teniposide | 50 mg | PA Required |
| Q2043 | SIPLEUCEL-T AUTO CD54+ | N/A | PA Required |
| Q2050 | DOXORUBICIN INJ | 10 MG | PA Required |
| Q5107 | INJECTION BEVACIZUMAB-AWWB BIOSIMILAR | 10 MG | PA Required |
| Q5112 | INJECTION TRASTUZUMAB-DTTB BIOSIMILAR | 10 MG | Not a Covered Benefit |
| Q5113 | INJECTION TRASTUZUMAB-PKRB BIOSIMILAR | 10 MG | Not a Covered Benefit |
| Q5114 | INJECTION TRASTUZUMAB-DKST BIOSIMILAR | 10 MG | PA Required |
| Q5115 | INJECTION RITUXIMAB-ABBS BIOSIMILAR | 10 MG | Not a Covered Benefit |
| Q5116 | INJECTION TRASTUZUMAB-QYYP BIOSIMILAR | 10 MG | Not a Covered Benefit |
| Q5117 | INJECTION TRASTUZUMAB-ANNS BIOSIMILAR | 10 MG | Not a Covered Benefit |
| Q5118 | INJECTION BEVACIZUMAB-BVZR BIOSIMILAR | 10 MG | PA Required |
| Q5119 | INJ RITUXIMAB-PVVR BIOSIMILAR RUXIENCE | 10 MG | PA Required |
| Q5123 | INJECTION RITUXIMAB-ARRX BIOSIMILAR | 10 MG | PA Required |
| Q5126 | INJ BEVACIZUMAB-MALY BIOSIMILAR (ALYMSYS) | 10 MG | Not a Covered Benefit |
| Q5129 | INJECTION BEVACIZUMAB-ADCD BIOSIMILAR | 10 MG | Not a Covered Benefit |
| S0108 | MERCAPTOPURINE ORAL | 50 MG | Not a Covered Benefit |
|
| ESA |
|
|
| J0881 | INJECTION DARBEPOETIN ALFA NON-ESRD USE | 1 MCG | PA Required |
| J0885 | INJECTION EPOETIN ALFA FOR NON-ESRD USE | 1000 U | PA Required |
| J0888 | EPOETIN BETA NON ESRD | 1 MCG | Not a Covered Benefit |
| J0896 | INJECTION LUSPATERCEPT-AAMT | 0.25 MG | PA Required |
| Q5106 | INJECTION EPOETIN ALFA-EPBX BIOSIMILAR | 1000 U | PA Required |
|
| IRON |
|
|
| J1439 | INJ FERRIC CARBOXYMALTOS | 1MG | PA Required |
| J1750 | INJ IRON DEXTRAN | 50 MG | PA Required for Non-PAR Providers Only |
| J1756 | INJECTION IRON SUCROSE | 1 MG | PA Required for Non-PAR Providers Only |
| J2916 | INJ SODIM FERRIC GLUCONATE | 12.5 MG | PA Required for Non-PAR Providers Only |
| Q0138 | INJECTION, FERUMOXYTOL, FOR TREATMENT OF IRON DEFICIENCY | N/A | PA Required |
CODE | MEDICATION | DOSE | Utilization Management | |
|
| MYELOID GROWTH FACTOR |
|
|
| J1442 | INJ FILGRASTIM EXCL BIOSIMIL | 1 MCG | Not a Covered Benefit |
| J1447 | INJECTION TBO-FILGRASTIM | 1 MCG | Not a Covered Benefit |
| J1449 | INJECTION EFLAPEGRASTIM-XNST | 0.1 MG | PA Required |
| J2506 | INJECT PEGFILGRASTIM EXCLUDES BIOSIMILAR | 0.5 MG | PA Required |
| J2820 | INJ SARGRAMOSTIN (GM-CSF) | 50MCG | PA Required |
| Q5101 | INJECTION, ZARXIO | 1 MCG | Not a Covered Benefit |
| Q5108 | INJECTION PEGFILGRASTIM-JMDB BIOSIMILAR | 0.5 MG | PA Required |
| Q5110 | INJ FILGRASTIM-AAFI BIOSIMILR | 1 MCG | PA Required |
| Q5111 | INJECTION PEGFILGRASTIM-CBQV BIOSIMILAR | 0.5 MG | Not a Covered Benefit |
| Q5120 | INJECTION PEGFILGRASTIM-BMEZ BIOSIMILAR | 0.5 MG | Not a Covered Benefit |
| Q5122 | INJECTION PEGFILGRASTIM-APGF BIOSIMILAR | 0.5 MG | Not a Covered Benefit |
| Q5125 | INJECTION FILGRASTIM-AYOW BIOSIMILAR | 1 MCG | PA Required |
| Q5127 | INJECTION PEG-FPGK STIMUFEND BIOSIMILAR | 0.5 MG | Not a Covered Benefit |
| Q5130 | INJECTION PEG-PBBK FYLNETRA BIOSIMILAR | 0.5 MG | Not a Covered Benefit |
|
| SUPPORTIVE MEDICATION |
|
|
| C9047 | INJECTION, CAPLACIZUMAB-YHDP | 1 MG | PA Required |
| J2470 | INJECTION, PANTOPRAZOLE SODIUM | 40 MG | PA Required |
| J2472 | INJECTION, PANTOPRAZOLE SODIUM IN SODIUM CHLORIDE (Baxter) | 40 MG | PA Required for Non-PAR Providers Only |
| C9113 | INJECTION, PANTOPRAZOLE SODIUM, PER VIAL | 40 MG | Not a Covered Benefit |
| C9293 | Injection, glucarpidase | 10 u | Only covered at OP Hospital |
| J0171 | ADRENALIN EPINEPHRINE INJECT | 0.1 MG | PA Required for Non-PAR Providers Only |
| J0185 | INJECTION APREPITANT | 1 MG | PA Required |
| J0207 | Injection, amifostine | 500 mg | PA Required for Non-PAR Providers Only |
| J0208 | INJECTION SODIUM THIOSULFATE | 100 MG | PA Required |
| J0612 | INJECTION CALCIUM GLUCONATE NOS | 10 MG | PA Required for Non-PAR Providers Only |
| J0613 | INJECTION CAGLU NOT THERAP EQUIV TO J0612 | 10 MG | PA Required for Non-PAR Providers Only |
| J0630 | INJ CALCITONIN SALMON TO | 400 U | PA Required for Non-PAR Providers Only |
| J0780 | INJ PROCHLORPERAZINE TO | 10 MG | PA Required for Non-PAR Providers Only |
| J0895 | INJ DEFEROXAMINE MESYLATE | 500 MG PER 5 CC | PA Required for Non-PAR Providers Only |
|
| SUPPORTIVE MEDICATION |
|
|
| J1100 | INJ DEXMETHOSON SODIM PHOSHATE | 1 MG | PA Required for Non-PAR Providers Only |
| J1190 | INJ DEXRAZOXANE HYDROCHLORIDE PER | 250 MG | PA Required |
| J1200 | INJ DIPHENHYDRAMINE HCL TO | 50 MG | PA Required for Non-PAR Providers Only |
| J1260 | Injection, dolasetron mesylate | 10 mg | Not a Covered Benefit |
CODE | MEDICATION | DOSE | Utilization Management | |
| J1302 | INJECTION SUTIMLIMAB-JOME | 10 MG | PA Required |
| J1410 | INJ ESTROGEN CONJUGATED PER 25 MG | 25 MG | PA Required for Non-PAR Providers Only |
| J1437 | INJECTION FERRIC DERISOMALTOSE | 10 MG | PA Required |
| J1448 | INJECTION TRILACICLIB | 1 MG | PA Required |
| J1453 | FOSAPREPITANT INJECTION |
| PA Required |
| J1454 | INJ FOSNETUPITANT 235 MG AND PALONOSETRON 0.25 MG | 235/0.25 MG | PA Required |
| J1459 | INJ IVIG PRIVIGEN | 500 MG | PA Required |
| J1460 | INJ GAMMA GLOBULIN IM | 1 CC | PA Required |
| J1554 | INJECTION IMMUNE GLOBULIN ASCENIV | 500 MG | PA Required |
| J1555 | INJECTION IMMUNE GLOBULIN | 100 MG | PA Required |
| J1556 | INJ, IMM GLOB BIVIGAM | 500MG | PA Required |
| J1557 | GAMMAPLEX INJECTION | 500 MG | PA Required |
| J1558 | INJECTION IMMUNE GLOBULIN XEMBIFY | 100 MG | PA Required |
| J1560 | INJ GAMMA GLOBULIN IM OVER | 10 CC | PA Required |
| J1561 | GAMUNEX-C/GAMMAKED | 500 MG | PA Required |
| J1566 | IMMUNE GLOBULIN, POWDER | 500 MG | PA Required |
| J1568 | OCTAGAM INJECTION | 500 MG | PA Required |
| J1569 | GAMMAGARD LIQUID INJECTION | 500 MG | PA Required |
| J1572 | FLEBOGAMMA INJECTION | 500 MG | PA Required |
| J1575 | INJ IG/HYALURONIDASE | 100 MG IG | PA Required |
| J1576 | INJECTION IMMUNE GLOBULIN IV NON-LYOPH | 500 MG | PA Required |
| J1599 | IVIG NON-LYOPHILIZED, NOS | 500 MG | PA Required |
| J1627 | INJ GRANISETRON EXT-RLSE | 0.1 MG | PA Required |
| J1630 | INJ HALOPERIDOL TO 5 MG | 5 MG | PA Required for Non-PAR Providers Only |
| J1643 | INJECT HEPARIN SOD NOT THERAP EQUIV J1644 | 1000 U | PA Required for Non-PAR Providers Only |
| J1720 | INJ HYDROCORTISONE SODIUM SUCCINATE TO | 100 MG | PA Required for Non-PAR Providers Only |
| J1790 | INJ DROPERIDOL TO 5 MG | 5 MG | PA Required for Non-PAR Providers Only |
| J1930 | INJECTION LANREOTIDE | 1 MG | PA Required |
| J1932 | INJECTION LANREOTIDE | 1 MG | PA Required |
| J2212 | METHYLNALTREXONE INJECTION | PER VIAL | PA Required |
| J2353 | INJECTION, OCTREOTIDE, DEPOT FORM FOR INTRAMUSCULAR INJECTION | 1 MG | PA Required |
| J2354 | INJ OCTREOTIDE NON-DEPOT FORM SUBQ/IV INJ | 25 MCG | PA Required |
| J2405 | INJ ONDANSETRON HCL PER 1 MG | 1 MG | PA Required for Non-PAR Providers Only |
| J2425 | INJECTION PALIFERMIN | 50 MCG | PA Required |
| J2550 | INJ PROMETHAZINE HCL TO 50 MG | 50 MG | PA Required for Non-PAR Providers Only |
CODE | MEDICATION | DOSE | Utilization Management | |
| J2562 | PLERIXAFOR INJECTION | 1 MG | PA Required |
| J2765 | INJ METOCLOPRAMIDE HCL TO 10 MG | 10 MG | PA Required for Non-PAR Providers Only |
| J2780 | INJECTION, RANITIDINE HYDROCHLORIDE | 25 MG | PA Required for Non-PAR Providers Only |
|
| SUPPORTIVE MEDICATION |
|
|
| J2783 | INJECTION, RASBURICASE | 0.5 MG | PA Required |
| J2790 | RHO D IMMUNE GLOBULIN INJ | 300 MG | PA Required for Non-PAR Providers Only |
| J2792 | INJ RHO D IMMUNE GLOBULIN IV HUMAN | 100 IU | PA Required |
| J2802 | ROMIPLOSTIM INJECTION | 1 MCG | PA Required |
| J2919 | INJ METHYLPREDNISOLONE SODIUM SUCCINATE | 5 MG | PA Required for Non-PAR Providers Only |
| J3410 | INJ HYDROXYZINE HCL TO 25 MG | 25 MG | PA Required for Non-PAR Providers Only |
| J3411 | INJECTION, THIAMINE HCI | 100 MG | PA Required for Non-PAR Providers Only |
| J3420 | INJ VITAMIN B-12 CYANOCOBALAMIN TO 1000 MCG | 1000 MCG | PA Required for Non-PAR Providers Only |
| J3430 | INJ PHYTONADIONE (VIT K) PER 1 MG | 1 MG | PA Required for Non-PAR Providers Only |
| J3471 | INJECTION HYALURONIDASE OVINE PRESERVATIVE FREE /1 USP UNIT UP TO 999 | N/A | PA Required for Non-PAR Providers Only |
| J3475 | INJECTION, MAGNESIUM SULFATE, PER 500 MG | 500 MG | PA Required for Non-PAR Providers Only |
| J3480 | INJECTION, POTASSUIM CHLORIDE, PER 2 MEQ | 2 MEQ | PA Required for Non-PAR Providers Only |
| J3490 | UNCLASSIFIED DRUGS | N/A | PA Required for Non-PAR Providers Only |
| J3590 | UNCLASSIFIED BIOLOGICS | N/A | PA Required for Non-PAR Providers Only |
| J7510 | PREDNISOLONE ORAL PER 5 MG | 5 MG | PA Required for Non-PAR Providers Only |
| J7515 | CYCLOSPORINE, ORAL 25 MG | 25 MG | PA Required |
| J8499 | PRESCRIPTION DRUG-ORAL-NON-CHEMOTHERAPEUTIC-NOS | N/A | PA Required |
| J8501 | APREPITANT ORAL | 5 MG | PA Required |
| J8540 | DEXAMETHASONE ORAL | 0.25 MG | PA Required for Non-PAR Providers Only |
| J8655 | NETUPITANT 300 MG AND PALONOSETRON 0.5 MG ORAL | N/A | PA Required |
| J8670 | ROLAPITANT ORAL | 1MG | Not a Covered Benefit |
| J9216 | INTERFERON GAMMA 1-B INJ | N/A | PA Required |
| P9045 | INFUSION, ALBUMIN (HUMAN), 5%, 250 ML | N/A | No PA is required. |
| P9046 | INFUSION, ALBUMIN (HUMAN), 25%, 20 ML | N/A | No PA is required. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CODE | MEDICATION | DOSE | Utilization Management | |
| P9047 | INFUSION, ALBUMIN (HUMAN), 25%, 50 ML | N/A | No PA is required. |
| Q0163 | DIPHENHYDRAMINE HCL ORAL CHEMO ANTI-EMETIC | 50 MG | PA Required for Non-PAR Providers Only |
| Q0164 | PROCHLORPERAZINE MALEATE ORAL ANTI-EMETIC | 5 MG | PA Required for Non-PAR Providers Only |
| Q0167 | DRONABINOL ORAL APPRVD CHEMO ANTI-EMETIC | 2.5 MG | PA Required for Non-PAR Providers Only |
| Q0169 | PROMETHAZINE HCL ORAL CHEMO ANTI-EMETIC | 12.5 MG | PA Required for Non-PAR Providers Only |
| Q0177 | HYDROXYZINE PAMOATE 25 MG ORAL CHEMO ANTI-EMETIC | 25 MG | PA Required for Non-PAR Providers Only |
| Q0180 | Dolasetron mesylate, 100 mg, oral, FDA-approved prescription antiemetic, for use as a complete therapeutic substitute for an IV antiemetic at the time of chemotherapy treatment | N/A | PA Required for Non-PAR Providers Only |
| S0176 | HYDROXYUREA, ORAL | 500MG | Not a Covered Benefit |